Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.581 USD | -0.80% | -8.48% | -94.69% |
May. 24 | Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial | CI |
May. 06 | Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-94.69% | 182K | |
+8.38% | 114B | |
+10.13% | 104B | |
+1.08% | 22.57B | |
-11.69% | 22.5B | |
-10.39% | 17.95B | |
-41.90% | 16.48B | |
-16.00% | 15.82B | |
+2.28% | 13.55B | |
+20.54% | 10.99B |
- Stock Market
- Equities
- ALLR Stock
- News Allarity Therapeutics, Inc.
- Ladenburg Thalmann Downgrades Allarity Therapeutics to Neutral From Buy